Clinical Trials

JBCRG-03

Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer

Status
Study Closed

Objectives
To evaluate the effect and safety of Docetaxel followed by FEC as primary systemic chmeotehrapy

Subjects

Endpoints
Primary endpoint: Pathological responce, safety ,Secondary endpoints: Clinical response, Breast conserving rate, Overall survival, Disease free survival

Trial Period
Jul 2005 - Dec 2009 (Registration: 1 year, Follow-up study: 3 years)

Lead Principal Investigator
Hiroji Iwata (Department of Breast Oncology, Aichi Cancer Center Hospital)

Target Sample Size
130

Regimen
Doc75 q3wx4->FEC100q3W×4

Source of Funding
ACRO: Advanced Clinical Research Organization

Conference Presentation
Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial

Articles and Publications
Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer

UMIN-ID
C000000291

jRCT

Memo

COI Disclosure

Previous PageClinical TrialsNext Page